HMGB1 regulates Th17 cell differentiation and function in patients with psoriasis

Abstract

AbstractBackgroundPsoriasis is an immune‐mediated chronic inflammatory skin disease, in which T helper 17 (Th17) cells and its effective cytokine interleukin (IL)‐17A play a pivotal pathogenic role. High mobility group box 1 (HMGB1) is an important proinflammatory cytokine, which has been confirmed to be highly expressed in the peripheral circulation and epidermis tissues of psoriasis patients. The regulatory effect of HMGB1 on IL‐17A expression and function has been reported in some inflammatory and autoimmune diseases by the HMGB1‐Toll‐like receptor 4 (TLR4)‐interleukin (IL)‐23‐IL‐17A pathway. While, in the pathological environment of psoriasis, whether HMGB1 can exert the regulatory effect on IL‐17A is not clear.ObjectiveWe aimed to evaluate the role of HMGB1‐TLR4‐IL‐23‐IL‐17A pathway in the pathogenesis of psoriasis and explore the possible regulatory mechanism of HMGB1 on Th17 cell differentiation.MethodsSerum levels of HMGB1, TLR4, IL‐23, and IL‐17A were quantified in 50 patients with moderate‐to‐severe plaque psoriasis and 30 healthy controls. Peripheral blood mononuclear cells  were acquired from 10 severe psoriasis patients and administrated by different concentrations of recombinant‐HMGB1 (rHMGB1) to detect the Th17 cell percentage, mRNA and protein levels of TLR4, IL‐23, IL‐17A and retinoid‐related orphan receptor γt (RORγt).ResultsThe serum levels of HMGB1, TLR4, IL‐23, and IL‐17A in psoriasis patients were significantly higher than healthy controls, especially in severe patients, and positively correlated with the severity index. There were also positive correlations between every two detected indicators of HMGB1, TLR4, IL‐23, and IL‐17A. In vitro study, rHMGB1 can promote the elevated expression of Th17 cell percentage as well as TLR4, IL‐23, IL‐17A, and RORγt in a dose‐dependent manner.ConclusionHMGB1 can contribute to the pathogenesis of psoriasis by regulating Th17 cell differentiation through HMGB1‐TLR4‐IL‐23‐RORγt pathway, then promotes IL‐17A production and aggravates inflammation process. Targeting HMGB1 may be a possible potential candidate for the immunotherapy of psoriasis.